MicroPort® Attends at SOLACI-CACI 2021 with CardioFlow Medtech™ and Endovastec™

Buenos Aires, Argentina — From the 2nd to 6th of August, 2021, MicroPort® Scientific Corporation (MicroPort®) and its subsidiaries, CardioFlow Medtech™ and Endovastec™, presented their independently developed products at the 26th Annual Congress of the Latin American Society of Interventional Cardiology and 31st Annual Congress of the Argentine Society for Interventional Cardiology (SOLACI-CACI 2021), which was held virtually from Buenos Aires, Argentina. As Latin America’s largest academic congress on cardiology, SOLACI-CACI 2021 attracted experts in the field of cardiovascular interventions from both Latin America and across the globe.

During the SOLACI-CACI conference, MicroPort® showcased its cutting-edge solutions in coronary intervention, transcatheter aortic valve replacement as well as aorta and peripheral vascular surgery. Amongst those discussed were the Firebird 2® Rapamycin-Eluting Coronary CoCr Stent System (Firebird 2®), Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®), VitaFlow® Transcatheter Aortic Valve and Delivery System (VitaFlow® System) and Castor® Branched Aortic Stent-Graft System (Castor® stent).

Prof. Hernán Pavlovsky from Argentina presented the five-year results of the ERACI IV study for the Firebird 2® at the congress. By comparing ERACI IV (Firebird 2®) and ERACI III (Cypher/Taxus) using propensity score matching (PSM), the investigators successfully matched 108 patients from each study and found that patients receiving Firebird 2® had significantly lower mortality rate, incidence of death/MI/CVA, revascularization events and MACCE compared with patients receiving Cypher or Taxus. Further, data shows that Firebird 2® stent performed significantly better than competing products in terms of safety and efficacy, and no very late stent thrombosis (VLST) was observed in patients with ERACI IV.

At the closing symposium, Professor Alexandra Lansky of Yale University School of Medicine, spoke positively about the Firehawk®, stating that the four-year follow-up results of TARGET AC showed that Firehawk® demonstrated sustained efficacy and safety in an all-comers population. Among patients who discontinued the dual antiplatelet therapy (DAPT) in two years, the Firehawk® stent performed better in terms of safety compared to competing products.

Prof. Guangyuan Song of Beijing Anzhen Hospital Affiliated to Capital Medical University presented the results of a four-year clinical follow-up study for the VitaFlow® Transcatheter Aortic Valve and Delivery System (VitaFlow® System) developed by CardioFlow Medtech™. The results showed that VitaFlow® has an overall post-implantation mortality rate of 12.7%, which indicates excellent efficacy and safety in patients with severe aortic stenosis. On the same day as the satellite session, Prof. Matias Sztejfman of Sanatorio Guemes de Buenos Aires, Argentina completed the first implantation of VitaFlow® in Argentina, praising the valve highly. Prof. Junjie Zhang shared a challenging type 0 bicuspid case with severe calcification and high risk for coronary occlusion. Under coronary artery protection, a VitaFlow 27 valve was successfully implanted, and after 6 months of follow-up, the shape of valve frame was good, and the LVEF recovered from 41% to 72%.

In addition, Prof. Chang Shu, Director of Vascular Surgery Center of Fuwai Hospital of Chinese Academy of Medical Sciences, highlighted the significant advantages of Endovastec™’s Castor® stent – designed for simultaneous aorta and aortic arch repair through minimally invasive treatment – in reconstructing the left subclavian artery and summarized the single-center clinical cases and data.

Prof. Chang Shu commented, “The Castor® stent, as the world’s first aortic branch stent with excellent post-market clinical follow-up data, is the general choice for reconstructing the left subclavian artery and has become widely available in clinical applications in China.”

The conference demonstrated the solid foundation MicroPort® has laid for further developing the regional market of Latin America, with the overall aim of serving more patients worldwide with integrated medical solutions.

About MicroPort®

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), is a subsidiary of MicroPort Scientific Corporation (Group) Co., Ltd. (stock code: 00853.HK). As a leader in high-end innovative medical solutions, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA. In the future, MicroPort® will continue to pursue an innovative, people-centered culture to provide patients and physicians around the world with innovative high-end medical devices and integrated solutions.

About MicroPort® CardioFlow

Founded in 2015, CardioFlow Medtech (stock code: 02160.HK) specializes in total medical solutions for the treatment of the most common aortic and mitral valve diseases, including aortic stenosis and mitral regurgitation. Its independently developed VitaFlow® Transcatheter Aortic Valve and Delivery System received NMPA approval in July 2019. The new generation product, VitaFlow Liberty Transcatheter Aortic Valve and Delivery System, has processed registration and is under clinical trials in Europe. In clinical practices, VitaFlow® has been paired with CardioFlow Medtech’s proprietary Alwide® valve balloon dilation catheter and Alpass® catheter sheath, which have enabled CardioFlow Medtech to become the only medical device company in China that can provide a comprehensive offering of accessories for TAVI procedures.

About MicroPort Endovastec™

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™), which is a subsidiary of MicroPort Scientific Corporation, was founded in Shanghai SIMZ Century Medicine Park in 2012. Endovastec™ was granted Shanghai High-tech Enterprises, Shanghai Science and Technology Little Giant Enterprise, and the first batch of Specialized and New “Little Giant” Enterprise, AAA-level Credit Enterprise and Multinational R&D Center in China. Endovastec™ was listed on the STAR Market (Stock code: 688016) of the Shanghai Stock Exchange on July 22, 2019.